TD Asset Management
EUCRU

TD Asset Management’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

TD Asset Management’s Portfolio EUCRU Stock Details EUCRU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-43,657
Closed -$436K – 1525
2021
Q4 		$436K Hold
43,657
– – ﹤0.01% 1399
2021
Q3 		$435K Hold
43,657
– – ﹤0.01% 1412
2021
Q2 		$435K Hold
43,657
– – ﹤0.01% 1407
2021
Q1 		$440K Hold
43,657
– – ﹤0.01% 1418
2020
Q4 		$459K Buy
+43,657
New +$443K ﹤0.01% 1345

Other funds holding EUCRU

MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
CIM
Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return
SMA
Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

TD Asset Management's EUCRU Position: Q1 2022 in Review

TD Asset Management sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q1 2022, closing a stake of 43,657 shares — an estimated $436K sold.

TD Asset Management first reported a position in EUCRU in Q4 2020 and held it in 5 quarters. The position peaked at $459K in Q4 2020. 19 funds tracked by Wall St. Rank hold EUCRU as of Q1 2022.

  • TD Asset Management reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q1 2022 after selling out during the quarter.
  • TD Asset Management sold 43,657 Eucrates Biomedical Acquisition Corp. Unit shares in Q1 2022, an estimated $436K.
  • TD Asset Management first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q4 2020 and held it in 5 quarters.
  • TD Asset Management's Eucrates Biomedical Acquisition Corp. Unit position peaked at $459K in Q4 2020.
  • 19 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q1 2022.

Based on TD Asset Management's 13F filing for Q1 2022, filed 10 May 2022.